The efficient combined targeting of EGFR, SRC, STAT, and MAPK by 3, 3′- (3, 5-DCPBC) in melanoma cells may long term assist clinicians to prevent melanoma growth and even to overcome drug resistance. The gene discussed is EGFR; the disease is melanoma.